Healthcare / Medical DevicesNasdaqCM
$0.70
-0.01 (-0.85%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-18.4M · quality 75.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
30/100
D
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$54M
P/E
N/A
•EV/EBITDA
N/A
•ROE
201.9%
↑Gross Margin
-262.7%
↓Debt/Equity
-0.08
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2020–2025 · 5 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
-7626.6%
FCF / Net income
0.77x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $241000.0 · net income $-23.8M · FCF $-18.4M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Revenue | $241000.00 | $241000.00 | $225000.00 | $316000.00 | $237000.00 | — | — |
| Net Income | $-23.8M | $-23.8M | $-20.8M | $-29.9M | $-15.9M | $-251633.00 | — |
| EBITDA | $-21.9M | $-21.9M | $-19.8M | $-29.8M | $-8.6M | — | — |
| EPS | — | — | -1.49 | -2.54 | -1.57 | — | — |
| Gross Margin | -262.7% | -262.7% | -229.8% | -149.7% | -110.1% | — | — |
| Operating Margin | -9240.7% | -9240.7% | -8558.2% | -5809.8% | -3673.4% | — | — |
| Net Margin | -9857.3% | -9857.3% | -9242.2% | -9469.0% | -6718.6% | — | — |
| Balance Sheet | |||||||
| Debt/Equity | -0.08 | -0.08 | -1.04 | -0.32 | -0.95 | — | — |
| Current Ratio | 2.27 | 2.27 | — | — | — | — | — |
| Cash Flow | |||||||
| Free Cash Flow | $-18.4M | $-18.4M | $-18.9M | $-17.2M | $-9.0M | — | — |
| Returns | |||||||
| ROE | 201.9% | 201.9% | 110.4% | 1684.8% | 44.0% | 0.6% | — |
| Growth & Yield | |||||||
| Revenue Growth | 7.1% | 7.1% | -28.8% | 33.3% | — | — | — |
| EPS Growth | — | — | 41.3% | -62.0% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-54.0%
Start / end P/E
n/dx → n/dx
EPS bridge
-1.49 → n/d
Residual
-54.0%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.